Vaxcyte, Inc. PCVX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

52/100

2/6 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Vaxcyte, Inc. (PCVX) reported total assets of $3.05B and total liabilities of $360.46M for fiscal year 2025, resulting in total equity of $2.69B.

The company held $1.56B in cash and short-term investments. Total debt stood at $228.84M, with net debt of $54.88M. The Debt-to-Equity (D/E) ratio was 0.09 (conservative).

Current ratio is 7.91, indicating strong short-term liquidity.

Criteria supported by this page:

HEALTH (100/100, Pass) — Debt-to-Equity of 0.09, current ratio of 7.91 — balance sheet is strong
MOAT (40/100) — Total assets $3.05B and equity $2.69B support the company's competitive scale
VALUE (58/100) — Debt-to-Equity 0.09 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 51/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

52/100

SG Score

View full scorecard →

VALUE

58/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

100/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

40/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Vaxcyte, Inc. Balance Sheet History

Metric	FY2025	FY2024	FY2023	FY2022
Total Assets	$3.05B	$3.51B	$1.41B	$1.01B
Total Liabilities	$360.46M	$205.5M	$167.45M	$52.57M
Total Debt	$228.84M	$71.11M	$29.22M	$17.94M
Cash & Investments	$1.56B	$1.75B	$1.08B	$931.38M
Total Stockholders Equity	$2.69B	$3.31B	$1.24B	$953.61M